The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf 17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-BDNF, or VTvaf 17- VEGFA, or VTvafl7-BFGF, or VTvafl7-NGF, or VTvafl7-GDNF, or VTvafl7-NT3, or VTvafl7-CNTF, or VTvafl7-IGFl, has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. Each of the constructed gene therapy DNA vectors, namely VTvafl7-BDNF, or VTvaf 17- VEGFA, or VTvafl7-BFGF, or VTvafl7-NGF, or VTvafl7-GDNF, or VTvafl7-NT3, or VTvafl7- CNTF, or VTvafl7-IGFl has the ability to efficiently penetrate into cells and express the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes, respectively, and cloned to it due to the limited size of VTvaf 17 vector part not exceeding 3200 bp. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals.
